Adrafinil is a synthetic compound that was historically used as a wakefulness-promoting agent. It is a prodrug, meaning it is metabolized in the body into an active substance, in this case, modafinil. Developed in the 1970s, Adrafinil was initially marketed in France under the brand name Olmifon before being discontinued. It is primarily recognized for its stimulating effects, which are thought to improve alertness and reduce fatigue. Unlike some other stimulants, Adrafinil is not typically associated with hyperactivity or significant cardiovascular stimulation, though individual responses can vary. As a supplement, it is often discussed in relation to cognitive performance and general wakefulness. The information presented here is for educational purposes only and is not intended as medical advice (PubChem, DrugBank).
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Sources referenced
* Cochrane Reviews
* DrugBank
* Examine.com
* FDA (U.S. Food and Drug Administration)
* EMA (European Medicines Agency)
* Mayo Clinic
* NIH (National Institutes of Health)
* NIH National Institute on Drug Abuse (NIDA)
* PubChem
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the supplement category or studied for the same goals.
